Nguyen CL, et al. - Researchers gauged the incidence, characteristics and baseline predictors of poor visual outcomes in eyes with neovascular age-related macular degeneration (nAMD) receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in daily clinical practice. They used Kaplan-Meier curves to estimate time to first development of loss of ≥15 letters. Over 5 years of anti-VEGF therapy, 23% of eyes with nAMD developed sustained VA loss of ≥15 letters. More accurate assessment of the potential benefit from anti-VEGF therapy was provided by baseline predictors of poor outcomes.